The European Patent Office has issued patent number EP1534305B1 (TREATING CARTILAGE/BONE CONDITIONS WITH WATER-SOLUBLE STRONTIUM SALTS) has recently been issued to Osteologix, Inc. (OTC: OLGX).
The said patent, expiring in 2024, covers the use of strontium malonate for use in the treatment and/or prophylaxis of cartilage and/or bone conditions, including osteoporosis.
The invention covered by the patent relates to the use of strontium malonate for the treatment and/or prophylaxis of osteoporosis, osteopenia, Paget's disease, immobilization-induced osteopenia or osteoporosis, glucocorticoid-induced osteopenia or osteoporosis or the improvement of fracture healing after traumatic or atraumatic fracture, among other claims.
NB S101 --Osteologix's investigational drug for the treatment of osteoporosis- contains strontium malonate as its active ingredient.
Read the full press release.
Comment Preview